ストックスクリーナーアプリを入手
1.40
2.10%
-0.03
プレマーケット:
1.44
0.04
+2.86%
前日終値:
$1.43
開ける：
$1.53
24時間の取引高:
25,808
Relative Volume:
1.07
時価総額：
$131.36M
収益：
$3.13M
当期純損益:
$-55.77M
株価収益率:
-2.2783
EPS:
-0.6145
ネットキャッシュフロー:
$-61.24M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+2.19%
6か月 パフォーマンス:
-23.08%
1年 パフォーマンス:
-37.48%
1日の値動き範囲:
$1.40
$1.54
1週間の範囲:
$1.40
$1.57
52週間の値動き範囲:
$1.17
$2.63
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.40 | 134.18M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-09-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | 開始されました | BTIG Research | Buy |
| 2021-09-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 開始されました | Goldman | Neutral |
すべてを表示
Innate Pharma Adr (IPHA) 最新ニュース
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com India
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - MarketBeat
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline By Investing.com - Investing.com India
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Here’s What Happened - Defense World
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference - ChartMill
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Down 0.5%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3% – Should You Buy? - Defense World
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3%Should You Buy? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7%Should You Buy? - MarketBeat
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress - Investing.com
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com India
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com UK
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Should I buy Innate Pharma (IPHA) - Zacks Investment Research
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential By Investing.com - Investing.com South Africa
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Earnings call transcript: Innate Pharma Q4 2024 sees strategic advances By Investing.com - Investing.com South Africa
What Are Earnings Reports? - MarketBeat
Earnings call: Innate Pharma reports progress in drug development - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Pluri (PLUR) Short Interest & Short Float | Updated May 2026 $PLUR - MarketBeat
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
Annovis Bio (ANVS) Short Interest Ratio and Volume 2025 - MarketBeat
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - The Chronicle-Journal
Evaxion A/S (EVAX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
BioAtla (BCAB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Adr (IPHA) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):